Tracking infection and inflammation markers in hospitalized COVID-19 patients
Dynamics of Nucleocapsid Antigen Serum Levels and Other Markers of Infection and Inflammation in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients - a Pilot Study
This study looks at how different health factors affect the recovery of hospitalized COVID-19 patients by tracking their infection and inflammation markers.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | University Hospital Hradec Kralove Academic / other |
| Drugs / interventions | tocilizumab |
| Locations | 1 site (Hradec Králové) |
| Trial ID | NCT04887623 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the evolution of inflammatory markers and other clinical parameters in hospitalized patients suffering from moderate to severe COVID-19. It will include 30 patients who will be monitored for various factors such as age, comorbidities, treatment interventions, and laboratory markers indicating the severity of their infection. The study will focus on understanding how these factors influence the patients' responses to the viral infection and their overall outcomes during and after hospitalization.
Who should consider this trial
Good fit: Ideal candidates are hospitalized patients with a confirmed SARS-CoV-2 infection requiring respiratory support.
Not a fit: Patients with a known history of interstitial lung disease or congestive heart failure may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of COVID-19 patient responses and improve treatment strategies.
How similar studies have performed: Other studies have shown success in tracking inflammatory markers in COVID-19 patients, suggesting this approach is promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * SARS CoV2 positive test within last 14 day * bilateral infiltrates on chest X.ray or CT * need for oxygen to keep pulse oximetry saturation above 92% or other respiratory support measures (HFNO, non-invasive ventilation or invasive ventilation) Exclusion Criteria: * known history of intersticial lung disease * known history of congestive heart failure
Where this trial is running
Hradec Králové
- University Hospital Hradec Kralove — Hradec Králové, Czechia (Recruiting)
Study contacts
- Study coordinator: Pavel Dostál, MD, PhD
- Email: pavel.dostal@fnhk.cz
- Phone: +420602455632
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.